Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more
Protara Therapeutics Inc (TARA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.094x
Based on the latest financial reports, Protara Therapeutics Inc (TARA) has a cash flow conversion efficiency ratio of -0.094x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.45 Million) by net assets ($132.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Protara Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Protara Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Protara Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protara Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Boryung Pharm
KO:003850
|
0.060x |
|
PERMA-PIPE INTL HLDGS
F:MF3
|
N/A |
|
John Mattson Fastighetsforetagen AB
ST:JOMA
|
0.008x |
|
Vizionfocus Inc.
TW:4771
|
0.059x |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
-0.086x |
|
Curacle Co. Ltd.
KQ:365270
|
-0.092x |
|
NEXCOM International Co Ltd
TWO:8234
|
0.017x |
|
I-PEX Inc.
OTCGREY:DAIKF
|
N/A |
Annual Cash Flow Conversion Efficiency for Protara Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Protara Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $167.13 Million | $-35.81 Million | -0.214x | +61.03% |
| 2023-12-31 | $68.32 Million | $-37.56 Million | -0.550x | -112.10% |
| 2022-12-31 | $102.08 Million | $-26.46 Million | -0.259x | -21.63% |
| 2021-12-31 | $161.91 Million | $-34.50 Million | -0.213x | -81.38% |
| 2020-12-31 | $199.24 Million | $-23.41 Million | -0.117x | +95.20% |
| 2019-12-31 | $6.39 Million | $-15.65 Million | -2.448x | -115.38% |
| 2018-12-31 | $20.44 Million | $-23.23 Million | -1.136x | -76.63% |
| 2017-12-31 | $34.74 Million | $-22.35 Million | -0.643x | -4.42% |
| 2016-12-31 | $38.44 Million | $-23.69 Million | -0.616x | -122.42% |
| 2015-12-31 | $63.41 Million | $-17.57 Million | -0.277x | -128.68% |
| 2014-12-31 | $82.46 Million | $-9.99 Million | -0.121x | -107.43% |
| 2013-12-31 | $-4.11 Million | $-6.70 Million | 1.631x | +171.92% |
| 2012-12-31 | $3.63 Million | $-8.23 Million | -2.268x | -- |